Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

Hepatology Research

Volumn 40, Issue 2, 2010, Pages 125-134

  Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Yatsuji, Hiromi ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Kobayashi, Masahiro ^a   Kawamura, Yusuke ^a   Suzuki, Yoshiyuki ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Mineta, Rie ^a   Iwasaki, Satomi ^a   Watahiki, Sachiyo ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Alanine transaminase; Breakthrough hepatitis; Hepatitis B virus; Lamivudine; Mutation; Viral DNA

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; BREAKTHROUGH HEPATITIS; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL;

EID: 77954351634     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00565.x     Document Type: Article

References (23)

1. Dienstag JL, Schiff ER, Wright TL. Lamivudine as initial treatment for chronic hepatitis b in the United states. N Engl J Med 1999, 341:1256-63.
2. Lai CL, Ching CK, Tung AK. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997, 25:241-4.
3. Nevens F, Main J, Honkoop P. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997, 113:1258-63.
4. Suzuki Y, Kumada H, Ikeda K. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999, 30:743-8.
5. Li MW, Hou W, Wo JE, Liu KZ. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B 2005, 6:664-7.
6. Pallier C, Castera L, Soulier A. Dynamics of hepatitis B virus resistance to lamivudine. J Virol 2006, 80:643-53.
7. Allen MI, Deslauriers M, Andrews CW. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-7.
8. Chayama K, Suzuki Y, Kobayashi M. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998, 27:1711-16.
9. Honkoop P, Niesters HG, De Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997, 26:1393-5.
10. Gaillard RK, Barnard J, Lopez V. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother 2002, 46:1005-13.
11. Bottecchia M, Souto FJ, KM O. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. BMC Microbiol 2008, 8:11-20.
12. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008, 28:167-77.
13. Kumada H. Scientific Research Grant of Ministry of Health, Labour and Welfare Research of Hepatitis Overcome Urgent Strategy. 2007, Research Report of the Standardization of ViralHepatitis treatment including Liver Cirrhosis (Japanese version
14. Buster EH, van Erpecum KJ, Schalm SW. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Neth J Med 2008, 66:292-306.
15. Tadokoro K, Kobayashi M, Yamaguchi T. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Methods 2006, 138:30-9.
16. Liu KZ, Hou W, Zumbika E, Ni Q. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Sci B 2005, 6:1182-7.
17. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999, 30:770-4.
18. Kumada H. Continued lamivudine therapy in patients with chronic hepatitis B. Intervirology 2003, 46:377-87.
19. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 2002, 9:393-9.
20. Kobayashi M, Akuta N, Suzuki F. Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 2006, 78:60-7.
21. Suzuki F, Tsubota A, Arase Y. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003, 46:182-9.
22. Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. World J Gastroenterol 2008, 14:4416-19.
23. Matsuda M, Suzuki F, Suzuki Y. YMDD mutant in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 2004, 74:361-6.